Inicio・Lista de Acciones・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Cerrado

SectorSanidad

183.51 1.04

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

178.31

Máximo

183.9

Métricas clave
By Trading Economics
Ingresos	-89M -454M
BPA	-2.29
Empleados	883
EBITDA	-89M -437M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+10.45% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	7.7B 39B
Apertura anterior	182.47
Cierre anterior	183.51

Noticias sobre sentimiento de mercado

By Acuity

79%

21%

316 / 340 Clasificación en Healthcare

REVOLUTION Medicines Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 jul 2026, 17:31 UTC

Social Media

News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Comparación entre iguales

Cambio de precio

REVOLUTION Medicines Inc previsión

Precio Objetivo

By TipRanks

10.45% repunte

Estimación a 12 Meses

Media 199.24 USD 10.45%

Máximo 263 USD

Mínimo 151 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

316 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.